Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07614893 · ClinicalTrials.gov registry record · NA
Clinician Notification to Increase Aspirin Prophylaxis for Preeclampsia Prevention
A NA study, sponsored by Massachusetts General Hospital.
- Not yet
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
NCT07614893: Clinical Trial NA study, sponsored by Massachusetts General Hospital.
NCT07614893 is a NA study that has not yet begun recruiting, run by Massachusetts General Hospital. The registered enrollment target is 1,000 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (29% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07614893, a NA study, has not yet begun recruiting, sponsored by Massachusetts General Hospital.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
Study Summary
Preeclampsia is a leading cause of maternal morbidity and mortality. Low-dose aspirin prophylaxis reduces preeclampsia risk among high-risk pregnant individuals but remains underused in routine clinical practice. This pragmatic cluster-randomized implementation trial will test whether clinician notification of elevated preeclampsia risk increases aspirin prophylaxis utilization among eligible pregnant individuals receiving outpatient obstetric care. Clusters will be randomized to clinician notification versus usual care. In the intervention arm, obstetric clinicians will receive notification that a patient is at elevated risk for preeclampsia and a recommendation to consider initiation of aspirin prophylaxis between 12 and 28 weeks' gestation, as clinically appropriate. The intervention does not assign participants to aspirin and does not require any study-mandated medication. All decisions regarding aspirin prophylaxis will remain at the discretion of the treating obstetric clinician and patient.
Primary Outcome
Proportion of eligible patient encounters with evidence of aspirin prophylaxis utilization, defined as aspirin prescription, aspirin documented on the medication list, or clinician documentation recommending aspirin prophylaxis during the eligible gestational window.
Interventions
- BEHAVIORAL Clinician notification of elevated preeclampsia risk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2027-05 |
| Est. Completion | 2030-05 |
| Phase | NA |
What is known before NCT07614893 opens enrollment
NCT07614893 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (29% lower).
The record links to 0 conditions, and to 1 intervention - of which Clinician notification of elevated preeclampsia risk is the first listed.
NCT07614893 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07614893 about?
NCT07614893 is a clinical study titled "Clinician Notification to Increase Aspirin Prophylaxis for Preeclampsia Prevention". Preeclampsia is a leading cause of maternal morbidity and mortality. Low-dose aspirin prophylaxis reduces preeclampsia risk among high-risk pregnant individuals but remains underused in routine clinical practice. This pragmatic cluster-randomized implementation trial will test whether clinician noti...
What is the current status of trial NCT07614893?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2027-05. Estimated completion is 2030-05.
What interventions are being tested in trial NCT07614893?
The interventions under investigation include: Clinician notification of elevated preeclampsia risk (BEHAVIORAL).
Who is sponsoring clinical trial NCT07614893?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07614893's enrollment target sits among peer trials
1,000 107th of 2000 higher than 1,880 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia